HspE7 plus Poly-ICLC: Phase I data

Data from the fourth and last cohort of patients in an open-label, U.S. Phase I trial showed that after 5 weeks, 500 µg of HspE7 plus 2,000 µg of Poly-ICLC was well tolerated. The study enrolled 17 pa...